CDK7 and neuroblastoma: Recent studies showed that the combination of a bromodomain inhibitor with a CDK7 inhibitor, an AURKA inhibitor or an HDAC inhibitor is significantly more effective in suppressing MYCN-driven NB tumor growth than either drug alone (88, 102, 103).